RESPIRARE - Efficacy and Safety of Cudetaxestat in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
The overall objective of this study is to evaluate the effectiveness and safety of cudetaxestat (BLD-0409) as compared to placebo with or without standard of care (nintedanib or pirfenidone) in subjects with idiopathic pulmonary fibrosis (IPF)
Epistemonikos ID: aed80ddd18912cc92c8d1316a38967d8fa6f260a
First added on: May 13, 2024